The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GNLX | +156.21% | N/A | N/A | +32% |
| S&P | +17.53% | +93.66% | +14.13% | +67% |
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.
The company's shares rose on signs it might be getting closer to its first biologics license application.
The company reported positive phase 2 trial news regarding its lead therapy.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.14M | 29.9% |
| Gross Margin | -3000.00% | 0.0% |
| Market Cap | $108.30M | 61.7% |
| Market Cap / Employee | $4.51M | 54.9% |
| Employees | 24 | 0.0% |
| Net Income | -$7.46M | -13.4% |
| EBITDA | -$7.65M | -14.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.55M | -16.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.36M | -20.3% |
| Short Term Debt | $0.35M | -31.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -78.50% | -9.2% |
| Return On Invested Capital | 541.40% | -41.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.17M | -1.7% |
| Operating Free Cash Flow | -$7.06M | -3.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.17 | 2.46 | 3.57 | 3.63 | 3.96% |
| Price to Sales | 21580.48 | 7236.78 | 10230.21 | 10244.80 | 364.04% |
| Price to Tangible Book Value | 2.17 | 2.46 | 3.57 | 3.63 | 3.97% |
| Enterprise Value to EBITDA | -7.42 | -5.56 | -7.94 | -10.80 | 173.03% |
| Return on Equity | -96.9% | -130.6% | -131.4% | -98.7% | 11.46% |
| Total Debt | $2.04M | $1.87M | $1.79M | $1.71M | -22.70% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
